OBJECTIVE: Pulmonary function frequently deteriorates after cardiopulmonary bypass (CPB). Chronic obstructive pulmonary disease (COPD) increases risk of respiratory complications after CPB. Cysteinyl leukotrienes are important mediators of respiratory dysfunction. Their role during cardiac surgery and its lung complications is incompletely understood. We studied whether production of cysteinyl leukotrienes changes during and after cardiac surgery with CPB and differs between patients with and without COPD. METHODS: Patients with (n = 9) and without (n = 10) moderate-to-severe COPD undergoing cardiac surgery with CPB were prospectively included. Plasma and urinary cysteinyl leukotriene and leukotriene B(4) concentrations were measured by enzyme-linked immunosorbent assay after anesthesia induction, at end of CPB, after CPB, and 2 hours after intensive care unit admission. Gas exchange and respiratory mechanics were also assessed. RESULTS: Patients with COPD had larger airway resistances after CPB and chest closure (P < .001), lower ratio of arterial Po(2) to inspired oxygen fraction at intensive care unit admission (215 ± 37 vs 328 ± 30 mm Hg, P < .05), and longer postoperative mechanical ventilation (13.7 ± 5.8 vs 6.8 ± 3.4 hours, P < .01). Urinary cysteinyl leukotriene concentrations increased with time in both groups (P < .01), but more in patients with than without COPD (P < .05). Plasma cysteinyl leukotriene concentrations increased significantly between baseline and intensive care unit admission in patients with but not without COPD (P < .01). Concentrations of leukotriene B(4) in plasma and urine did not increase significantly with time and were not different between groups. CONCLUSIONS: Release of cysteinyl leukotrienes increases during cardiac surgery with CPB and is larger in patients with than without COPD. This may be related to higher lung and airway production of cysteinyl leukotrienes and neutrophil activation in patients with COPD.
OBJECTIVE: Pulmonary function frequently deteriorates after cardiopulmonary bypass (CPB). Chronic obstructive pulmonary disease (COPD) increases risk of respiratory complications after CPB. Cysteinyl leukotrienes are important mediators of respiratory dysfunction. Their role during cardiac surgery and its lung complications is incompletely understood. We studied whether production of cysteinyl leukotrienes changes during and after cardiac surgery with CPB and differs between patients with and without COPD. METHODS:Patients with (n = 9) and without (n = 10) moderate-to-severe COPD undergoing cardiac surgery with CPB were prospectively included. Plasma and urinary cysteinyl leukotriene and leukotriene B(4) concentrations were measured by enzyme-linked immunosorbent assay after anesthesia induction, at end of CPB, after CPB, and 2 hours after intensive care unit admission. Gas exchange and respiratory mechanics were also assessed. RESULTS:Patients with COPD had larger airway resistances after CPB and chest closure (P < .001), lower ratio of arterial Po(2) to inspired oxygen fraction at intensive care unit admission (215 ± 37 vs 328 ± 30 mm Hg, P < .05), and longer postoperative mechanical ventilation (13.7 ± 5.8 vs 6.8 ± 3.4 hours, P < .01). Urinary cysteinyl leukotriene concentrations increased with time in both groups (P < .01), but more in patients with than without COPD (P < .05). Plasma cysteinyl leukotriene concentrations increased significantly between baseline and intensive care unit admission in patients with but not without COPD (P < .01). Concentrations of leukotriene B(4) in plasma and urine did not increase significantly with time and were not different between groups. CONCLUSIONS: Release of cysteinyl leukotrienes increases during cardiac surgery with CPB and is larger in patients with than without COPD. This may be related to higher lung and airway production of cysteinyl leukotrienes and neutrophil activation in patients with COPD.
Authors: M K Ilton; P E Langton; M L Taylor; N L Misso; M Newman; P J Thompson; J Hung Journal: J Thorac Cardiovasc Surg Date: 1999-11 Impact factor: 5.209
Authors: S C Gardner; G K Grunwald; J S Rumsfeld; T Mackenzie; D Gao; J B Perlin; G McDonald; A L Shroyer Journal: Ann Thorac Surg Date: 2001-12 Impact factor: 4.330
Authors: F Mitsunobu; T Mifune; Y Hosaki; K Ashida; H Tsugeno; M Okamoto; S Takata; Y Tanizaki Journal: J Allergy Clin Immunol Date: 2001-03 Impact factor: 10.793
Authors: Robert A Clough; Bruce J Leavitt; Jeremy R Morton; Stephen K Plume; Felix Hernandez; William Nugent; Stephen J Lahey; Cathy S Ross; Gerald T O'Connor Journal: Arch Surg Date: 2002-04
Authors: Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski Journal: Am J Respir Crit Care Med Date: 2007-05-16 Impact factor: 21.405
Authors: Alysson R Carvalho; Fumito Ichinose; Ivany A Schettino; Dean Hess; Javier Rojas; Antonio Giannella-Neto; Arvind Agnihotri; Jennifer Walker; Thomas E MacGillivray; Marcos F Vidal Melo Journal: Lung Date: 2011-09-28 Impact factor: 2.584
Authors: Francesca Colazzo; Paolo Gelosa; Elena Tremoli; Luigi Sironi; Laura Castiglioni Journal: Mediators Inflamm Date: 2017-08-28 Impact factor: 4.711
Authors: Dashuai Wang; Su Wang; Yifan Du; Yu Song; Sheng Le; Hongfei Wang; Anchen Zhang; Xiaofan Huang; Long Wu; Xinling Du Journal: Front Cardiovasc Med Date: 2022-01-28